19 June 2013
Keywords: isentress, cuts, viral, load, untreated, patients, drug
Article | 03 November 2008
US drug major Merck & Co's Isentress (raltegravir) reduced HIV viral load to undetectable levels in 86% of patients compared to 82% for ...
Enjoying this article? To continue reading you need to login or subscribe.
Subscriptions are £60 per month, pay as you go.
Find out more details.
3 November 2008
18 June 2013
© 2013 thepharmaletter.com